Journal article

Evidence that the MEK/ERK but not the PI3K/Akt pathway is required for protection from myocardial ischemia-reperfusion injury by 3′,4′-dihydroxyflavonol

CJ Thomas, NR Lim, A Kedikaetswe, YY Yeap, OL Woodman, DCH Ng, CN May

European Journal of Pharmacology | ELSEVIER | Published : 2015

Abstract

The novel pro-drug of 3′4′-dihydroxyflavonol, NP202, potently reduces myocardial infarct size resulting from ischemia-reperfusion (I/R) through mechanisms that remain to be fully defined. In this study, we investigated whether cardioprotection induced by NP202 depended on activation of the reperfusion injury survival kinase (RISK) pathways. We therefore examined the effects of PD98059 and LY294002, specific inhibitors of the MEK/ERK1/2 and PI3K/Akt pathways, respectively. In isolated cardiomyocytes, H2O2induced oxidative stress activated ERK1/2 and this was further enhanced by DiOHF, the active parent compound of NP202. Although oxidative stress did not stimulate Akt in cardiomyocytes, co-tr..

View full abstract

University of Melbourne Researchers